Tag - VNRX

Developments

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...

March 6, 2026

Markets

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

March 14, 2018

Tag - VNRX

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx closes $8.4-million stock offering

Subscribe